Executive Team
Richard Muruve
CEO, DIRECTOR &
CO-FOUNDER
Mr. Muruve co-founded Arch Biotech Inc. with the Arch Inflammation team in 2006. Arch Biotech operated as a private company for four years and motivated the formation of Arch Biopartners in 2010. At that time, Arch Biopartners simultaneously acquired the commercial rights to the brain tumour targeting and peptide-solid surface technology platforms, launching the portfolio approach to drug development that Arch continues to oversee today. Prior to Arch Biotech, Mr. Muruve was a Vice President at Bank of Montreal where he spent 12 years in the Investment Banking Group. Mr. Muruve has a MBA from the University of British Columbia.
Dr. Daniel Muruve Ph. D
Chief Science Officer (CSO)
Co-Founder
Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from the Faculty of Medicine at the University of Manitoba in 1989 and has undertaken extensive post-graduate medical and scientific training over 10 years at the University of Calgary, Harvard University and the University of Lausanne. Dr. Muruve is a certified kidney specialist and a basic scientist with expertise in the biology of kidney disease and the molecular basis of inflammation and the immune system. He is an AHFMR Clinical Senior Scholar and holds a Canada Research Chair in Inflammation and Kidney Disease.
Andrew Bishop
Chief Financial Officer, Director
Mr. Bishop is a Partner and Co-Founder of Bingley Capital Inc., and brings over 20 years of experience in advising biotech and health care companies. He has worked on over 100 financing and M&A transactions over his career. Prior to establishing Bingley Capital in 2009, he held senior roles in investment banking, including Head of Health Care Investment Banking at HSBC Securities (Canada) Inc., where he covered biotech, pharma, and specialty pharma companies. He started his career in investment banking focused on companies in Quebec. For the past 9 years, Mr. Bishop has also served as a Director and Chair of Willow Breast & Hereditary Cancer Support, a not-for-profit organization focused on breast and hereditary cancer. Mr. Bishop received an International M.B.A. (with Distinction) from the Schulich School of Business at York University, and a Bachelor of Arts in Political Science and Economics from McGill University. He also received his Chartered Financial Analyst designation.
Aaron Benson
Director of Communications
Aaron’s career in communications and design has included the delivery of design systems, interface design, user experience, and front-end development. His track record as a creative director includes successful digital campaigns for a diverse range of corporate and business clients in sectors such as finance, insurance, technology, biotech, engineering, and real estate. Initially trained at Dreadnaught Design in Toronto, he developed an approach and aesthetic deeply influenced by modernist Canadian design principles. His leadership roles in multiple studios and communications teams has involved managing substantial brand systems and marketing campaigns for prominent financial institutions, along with national clients in arts, dance, theatre, and philanthropy. In his current role at Arch, Aaron continues to merge traditional design techniques with modern technology, creative and digital practices to deliver a concise and clear voice for the company.
Dr. Arthur Lau Ph. D
SENIOR PROJECT MANAGER
Arthur Lau is a Senior Project Manager of Clinical Trials at Arch Biopartners and a Research Scientist in Dr. Daniel Muruve’s research program. He completed a B.Sc. with Honours at the University of Toronto and a Ph.D. at the University of Western Ontario with a focus on kidney transplantation and immunology. As a postdoctoral fellow at the University of Calgary under the mentorship of Dr. Muruve, he continued his research on acute kidney injury and immunology including publications describing the use of LSALT peptide in renal disease. His current research focus is on elucidating mechanisms of immune surveillance in the kidney and developing therapeutics against acute kidney injury. Arthur joined the Arch Biopartners’ team as a Project Manager primarily managing the development of the LSALT peptide/Metablok portfolio and its related technologies.
